{"filing":{"accession_number":"0001213900-26-110531","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"ea0309003-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026110531/ea0309003-6k_alpha.htm"},"events":[{"id":36019,"run_id":33207,"accession_number":"0001213900-26-110531","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The press release announces FDA approval of an IDE supplement expanding the REGAIN clinical trial from 10 to 20 patients and adding new study endpoints, along with acceptance of trial data for presentation at a major scientific conference. This is a material regulatory and clinical milestone for a clinical-stage medical device company, but does not fit the specific event categories (not an earnings release, executive change, M\u0026A, impairment, or other named types). It represents a significant operational advancement in the company's clinical development program for its Alpha DaRT technology.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40289,"accession_number":"0001213900-26-110531","item_number":"EX-99.1","item_title":"ea030900301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces FDA approval of an IDE supplement expanding the REGAIN clinical trial from 10 to 20 patients and adding new study endpoints, along with acceptance of trial data for presentation at a major scientific conference. This is a material regulatory and clinical milestone for a clinical-stage medical device company, but does not fit the specific event categories (not an earnings release, executive change, M\u0026A, impairment, or other named types). It represents a significant operational advancement in the company's clinical development program for its Alpha DaRT technology.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T14:26:37.838560+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40289,"accession_number":"0001213900-26-110531","item_number":"EX-99.1","item_title":"ea030900301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces FDA approval of an IDE supplement expanding the REGAIN clinical trial from 10 to 20 patients and adding new study endpoints, along with acceptance of trial data for presentation at a major scientific conference. This is a material regulatory and clinical milestone for a clinical-stage medical device company, but does not fit the specific event categories (not an earnings release, executive change, M\u0026A, impairment, or other named types). It represents a significant operational advancement in the company's clinical development program for its Alpha DaRT technology.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T14:26:37.838560+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-10-19"}]}